explore -WSS

explore

author：leisure time 2025-09-27 23:01:38 - browse：37

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： American taxpayers paid $1.8 trillion in health care costs in 2022

hotspot

WSS

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Biohaven protein

Scientists successfully use ultrasound imaging to map brain activity

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Merck to acquire Harpoon Therapeutics for $680 million

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Allen Institute goes after foundational questions, CEO Costa says

How one medical school became remarkably diverse

iTeos Therapeutics debuts first data on TIGIT

Jerome Adams on the need for new antivirals for Covid

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Cancer drug shortages should be causing more outrage

Prosthetic arm enables patients to feel the objects they grip

Hepatitis C has a cure — but many Americans still lack access to it

AI used to predict Covid

focus

Study suggests new cause of Down syndrome: cells linked to aging

Physician assistants need a new name. Here's what it should be

Akili, maker of video game for ADHD, to be acquired for 34 million

Gene therapy denied for Afghan refugee whose father aided U.S.

Male doctors called my cancer incurable. A female doctor showed it wasn't

Insmed lung disease drug hits target in key Phase 3 trial

hotspot

focus

hotspot

leisure time